Therapeutic Drugs and Vaccine Development Research Center, National Institute of Infectious Diseases, Toyama-ku, Shinjuku, Tokyo, Japan.
School of Life Science and Technology, Tokyo Institute of Technology, Nagatsutacho, Yokohama, Japan.
Microbiol Spectr. 2024 Jun 4;12(6):e0042723. doi: 10.1128/spectrum.00427-23. Epub 2024 May 2.
O157:H7 is a globally important foodborne pathogen with implications for food safety. Antibiotic treatment for O157 may potentially contribute to the exacerbation of hemolytic uremic syndrome, and the increasing prevalence of antibiotic-resistant strains necessitates the development of new treatment strategies. In this study, the bactericidal effects and resistance development of antibiotic and bacteriophage monotherapy were compared with those of combination therapy against O157. Experiments involving continuous exposure of O157 to phages and antibiotics, along with genetic deletion studies, revealed that the deletion of and significantly increased resistance to fosfomycin. Furthermore, we found that OmpC functions as a receptor for the PP01 phage, which infects O157, and FhuA functions as a receptor for the newly isolated SP15 phage, targeting O157. In the and deletion mutants, additional deletion in , the receptor for the PP01 phage, increased resistance to fosfomycin. These findings suggest that specific phages may contribute to antibiotic resistance by selecting the emergence of gene mutations responsible for both phage and antibiotic resistance. While combination therapy with phages and antibiotics holds promise for the treatment of bacterial infections, careful consideration of phage selection is necessary.IMPORTANCEThe combination treatment of fosfomycin and bacteriophages against O157 demonstrated superior bactericidal efficacy compared to monotherapy, effectively suppressing the emergence of resistance. However, mutations selected by phage PP01 led to enhanced resistance not only to the phage but also to fosfomycin. These findings underscore the importance of exercising caution in selecting phages for combination therapy, as resistance selected by specific phages may increase the risk of developing antibiotic resistance.
O157:H7 是一种具有全球重要意义的食源性病原体,对食品安全有影响。针对 O157 的抗生素治疗可能会导致溶血性尿毒症综合征恶化,而抗生素耐药菌株的流行率不断上升,需要开发新的治疗策略。在这项研究中,比较了抗生素和噬菌体单药治疗与联合治疗对 O157 的杀菌效果和耐药性发展。通过连续暴露 O157 于噬菌体和抗生素的实验,以及基因缺失研究,发现缺失 和 显著增加了对磷霉素的耐药性。此外,我们发现 OmpC 作为感染 O157 的 PP01 噬菌体的受体,而 FhuA 作为新分离的 SP15 噬菌体的受体,靶向 O157。在 和 缺失突变体中,PP01 噬菌体受体 的进一步缺失增加了对磷霉素的耐药性。这些发现表明,特定的噬菌体可能通过选择导致噬菌体和抗生素耐药性的基因突变来促进抗生素耐药性的产生。虽然噬菌体和抗生素的联合治疗为细菌感染的治疗提供了希望,但需要谨慎考虑噬菌体的选择。
重要性:与单药治疗相比,用磷霉素和噬菌体联合治疗 O157 表现出更好的杀菌效果,有效地抑制了耐药性的出现。然而,噬菌体 PP01 选择的突变不仅导致对噬菌体的耐药性增强,而且导致对磷霉素的耐药性增强。这些发现强调了在选择用于联合治疗的噬菌体时要谨慎,因为特定噬菌体选择的耐药性可能会增加产生抗生素耐药性的风险。
Appl Environ Microbiol. 2004-6
Appl Environ Microbiol. 2003-1
Appl Microbiol Biotechnol. 2004-4
NPJ Antimicrob Resist. 2024-10-10
Nat Commun. 2024-11-11
Food Sci Nutr. 2023-7-5
Antibiotics (Basel). 2021-8-18
FEMS Microbiol Rev. 2020-11-24
Diagn Microbiol Infect Dis. 2020-3
Front Microbiol. 2019-9-10